Lykan Bioscience Completes Capital Restructuring with WindRose Health to Expand End-to-End Cell and Gene Therapy Services

VCBeat (WeChat ID: vcbeat) has learned from foreign media that WindRose Health, a healthcare investment firm based in New York, USA, recently announced an equity recapitalization of Lykan Bioscience. Lykan Bioscience is a manufacturing services organization dedicated to providing end-to-end integrated solutions for biotechnology and biopharmaceutical companies, primarily offering production and logistics services in the field of cell and gene therapies.

It is reported that following this collaboration, WindRose Health will provide Lykan Bioscience with a series of funding support to help Lykan Bioscience maintain sustained growth and development. Lykan Bioscience will expand its business resources and complete the construction of a cGMP facility spanning more than 60,000 square feet. The facility will be used for clinical trials and specific commercial purposes. The specific terms of this transaction have not been disclosed.

Headquartered in Phoenix, Arizona, USA, Lykan Bioscience provides guaranteed high-quality products and services to companies in the biomedical industry, including clinical trials and commercial manufacturing. Lykan Bioscience has ushered in a new era for the industry by helping companies address challenges such as lack of innovation in R&D, costly pharmaceutical facilities, and operational inexperience. The company offers comprehensive services—including point-of-care solutions, technology transfer, quality testing, and supply chain management—to help client companies accelerate growth and reduce time-to-market.

“Lykan Bioscience’s vision is to provide high-quality, cost-effective manufacturing solutions for the pharmaceutical industry, enabling client companies to accelerate the development of cell and gene therapies and reach more patients,” said Tony Rotunno, CEO of Lykan Bioscience. “We are delighted to partner with WindRose Health to jointly establish end-to-end solutions in the field of cell and gene therapy manufacturing. As our company continues its rapid growth, WindRose Health will also derive greater value in the healthcare market.”

CJ Burnes, Partner at WindRose Health, stated, “We are delighted to collaborate with the experienced management team at Lykan Bioscience. Lykan Bioscience presents a highly attractive opportunity to support a differentiated emerging platform that delivers high-quality, integrated solutions for cell and gene therapies to a growing yet capacity-constrained market.”

Furthermore, in this capital restructuring, investment bank Covington Associates served as the financial advisor to Lykan Bioscience, while internationally renowned law firm McDermott Will & Emery acted as legal counsel to WindRose Health and Lykan Bioscience.

WindRose Health Investors, established in 2000 and headquartered in New York, USA, is a private equity investment firm. The firm primarily makes private equity investments in companies within the healthcare industry, leveraging over a decade of sector-specific investment experience to unlock new growth opportunities for its portfolio companies. Currently, WindRose Health Investors manages five investment funds with over $1.4 billion in assets under management.

(Compiled by Wang Chan)